|
Allogene Therapeutics Inc (NASDAQ: ALLO) |
|
Allogene Therapeutics Inc
ALLO's Fundamental analysis
Select the Comparisons :
|
|
Select the Ratio:
|
|
|
Allogene Therapeutics Inc 's sales fell
in the first quarter of 2025 from the same quarter a year ago.
Biotechnology & Pharmaceuticals industry recorded
growth of revenues by 11.96 %
Allogene Therapeutics Inc net loss decreased from $-65 millions, to $-60 millions in first quarter of 2025,
• More on ALLO's Growth
|
|
Allogene Therapeutics Inc realized a net loss in trailing twelve months.
Allogene Therapeutics Inc realized cash reduction of $ -0.04 per share in trailing twelve-month period. |
Company |
- |
PE TTM
|
Industry |
- |
PE TTM
|
|
Biotechnology & Pharmaceuticals industry's Price to Sales ratio is at 6.02.
• More on ALLO's Valuation
|
|
|
|
|
Allogene Therapeutics Inc realized net loss in trailing twelve months.
Allogene Therapeutics Inc realized cash outflow of $ -0.04per share in trailing twelve-month period. |
Company |
- |
PE TTM
|
Industry |
- |
PE TTM
|
|
Biotechnology & Pharmaceuticals industry's Price to Sales ratio is at 6.02.
Allogene Therapeutics Inc Price to Book Ratio is at 0.62 higher than Industry Avg. of -23410.1, and higher than S&P 500 Avg. of 0.01
• More on ALLO's Valuation
|
|
|
|
CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.
Copyright © 2025 CSIMarket, Inc. All rights
reserved.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com